OS Therapies Inc Files Prospectus Supplement for Resale of 5.87M Shares

What Happened
OS Therapies Incorporated filed a prospectus supplement on September 10, 2026 (part of its Form S-3, File No. 333-289443) covering the resale from time to time of up to 5,874,094 shares of common stock by the selling stockholders named in the supplement. The company filed this Current Report on Form 8-K (Item 8.01) to attach the legal opinion of its counsel, Olshan Frome Wolosky LLP, regarding the legality of the shares. The underlying Form S-3 was originally filed August 8, 2025 and declared effective August 25, 2025.

Key Details

• Prospectus Supplement filed: September 10, 2026 (covers resale of up to 5,874,094 common shares).
• Registration statement: Form S-3, File No. 333-289443 (filed Aug 8, 2025; declared effective Aug 25, 2025).
• Counsel opinion: Legal opinion of Olshan Frome Wolosky LLP included as Exhibit 5.1 (with consent included).

Why It Matters
This filing enables the named selling stockholders to resell shares "from time to time" under OS Therapies’ effective shelf registration; the company submitted the counsel opinion to confirm the legal validity of the shares being offered for resale. The report does not announce earnings, management changes, a merger, or new financing by the company—rather, it provides disclosure and legal documentation related to potential resale activity. Investors who want details on who may sell shares or timing should review the Prospectus Supplement itself.